OA01.01 Evaluation of the kinetics of systemic distribution of IV injected monoclonal antibodies modified to alter host mediated Fc interaction in the rhesus macaque modelOral Abstract SessionBroadly neutralizing antibodies
OA01.04 Serum IgA inhibits HIV-specific broadly neutralising antibody Fc functionsOral Abstract SessionBroadly neutralizing antibodies
OA03.02 Safety and PK of Potent Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed InfantsOral Abstract SessionBroadly neutralizing antibodies
OA03.03 Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081)Oral Abstract SessionBroadly neutralizing antibodies
OA03.04LB Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial (HVTN 703/HPTN 081 and HVTN 704/085)Oral Abstract SessionBroadly neutralizing antibodies
OA03.05LB HIV-1 bnAb M4008_N1 targets a novel site of vulnerability at the V3 crownOral Abstract SessionBroadly neutralizing antibodies
OA08.02 Vaccination induces maturation of diverse unmutated VRC01-class precursors to HIV-1 broadly neutralizing antibodies in an Ig-humanized mouse modelOral Abstract SessionBroadly neutralizing antibodies
OA08.03 Combinations of scFv of HIV bNAbs demonstrate high breadth and potency against a multiclade panel of virusesOral Abstract SessionBroadly neutralizing antibodies
PE02.01 Structure of a CD4 binding site directed antibody in a donor with broadly neutralizing antibodiesE-posterBroadly neutralizing antibodies
PE02.03 Antibody-Antigen Distance of Broadly Neutralizing HIV-1 Antibodies Correlates with Glycan-Shield Coverage of HIV-1 Envelope TrimerE-posterBroadly neutralizing antibodies
seek-warrow-warrow-eseek-e81 - 90 of 444 items